[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580655":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":37,"centralContacts":53,"locations":63,"responsibleParty":182,"collaborators":37,"id":184,"slug":185,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":37,"eligibilityCriteria":190,"healthyVolunteers":186,"sex":191,"minAge":192,"maxAge":37,"enrollmentInfo":193,"targetDuration":37,"studyType":196,"phases":197,"briefSummary":200,"conditions":201,"keywords":37,"overallStatus":80,"whyStopped":37,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},{"fullName":5,"class":6},"Immunocore Ltd","INDUSTRY",[8,14,20,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: IMC-R117C Monotherapy Dose-Escalation","EXPERIMENTAL","Participants receive IMC-R117C intravenous (IV) infusion.",[13],"Drug: IMC-R117C",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B: IMC-R117C Combination Dose-Escalation","Participants receive IMC-R117C IV infusion in combination with standard of care chemotherapy and antiangiogenic agent",[13,18,19],"Drug: Chemotherapy drug","Drug: Antiangiogenic Agent",{"label":21,"type":10,"description":22,"interventionNames":23},"Arm C: IMC-R117C Combination Dose-Escalation","Participants receive IMC-R117C IV infusion with targeted therapies",[13,24,25],"Drug: Kinase inhibitor","Drug: Monoclonal antibody",{"label":27,"type":28,"description":29,"interventionNames":30},"Arm D: Control Arm","ACTIVE_COMPARATOR","Participants receive standard of care chemotherapy and antiangiogenic agent",[18,19],[32,38,41,44,47,50],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","IMC-R117C","IV infusion",[9,15,21],null,{"type":33,"name":39,"description":35,"armGroupLabels":40,"otherNames":37},"Chemotherapy drug",[15,27],{"type":33,"name":39,"description":42,"armGroupLabels":43,"otherNames":37},"oral",[15],{"type":33,"name":45,"description":42,"armGroupLabels":46,"otherNames":37},"Kinase inhibitor",[21],{"type":33,"name":48,"description":35,"armGroupLabels":49,"otherNames":37},"Antiangiogenic Agent",[15,27],{"type":33,"name":51,"description":35,"armGroupLabels":52,"otherNames":37},"Monoclonal antibody",[21],[54,59],{"name":55,"role":56,"phone":57,"phoneExt":37,"email":58},"Immunocore Medical Information","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":60,"role":56,"phone":61,"phoneExt":37,"email":62},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",[64,78,87,98,106,115,125,135,144,154,164,169,177],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":37},"St Vincent's Hospital","ACTIVE_NOT_RECRUITING","Darlinghurst","Sydney","NSW 2010","Australia","AU",{"type":73,"coordinates":74},"Point",[75,76],151.21925,-33.87939,{"lat":76,"lon":75},{"facility":79,"status":80,"city":81,"state":37,"zip":37,"country":70,"countryCode":71,"cosmosGeoPoint":82,"geoPoint":86,"contacts":37},"Peter MacCallum Cancer Centre","RECRUITING","Melbourne",{"type":73,"coordinates":83},[84,85],144.96332,-37.814,{"lat":85,"lon":84},{"facility":88,"status":80,"city":89,"state":37,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":37},"Institut Jules Bordet","Anderlecht","1070","Belgium","BE",{"type":73,"coordinates":94},[95,96],4.31454,50.83619,{"lat":96,"lon":95},{"facility":99,"status":80,"city":100,"state":37,"zip":37,"country":91,"countryCode":92,"cosmosGeoPoint":101,"geoPoint":105,"contacts":37},"Universitair Ziekenhuis Gent","Ghent",{"type":73,"coordinates":102},[103,104],3.71667,51.05,{"lat":104,"lon":103},{"facility":107,"status":80,"city":108,"state":37,"zip":109,"country":91,"countryCode":92,"cosmosGeoPoint":110,"geoPoint":114,"contacts":37},"UZ Leuven","Leuven","3000",{"type":73,"coordinates":111},[112,113],4.70093,50.87959,{"lat":113,"lon":112},{"facility":116,"status":80,"city":117,"state":37,"zip":37,"country":118,"countryCode":119,"cosmosGeoPoint":120,"geoPoint":124,"contacts":37},"Universitaetsklinikum Heidelberg","Heidelberg","Germany","DE",{"type":73,"coordinates":121},[122,123],8.69079,49.40768,{"lat":123,"lon":122},{"facility":126,"status":80,"city":127,"state":37,"zip":37,"country":128,"countryCode":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":37},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma","Italy","IT",{"type":73,"coordinates":131},[132,133],11.10642,44.99364,{"lat":133,"lon":132},{"facility":136,"status":80,"city":137,"state":37,"zip":138,"country":128,"countryCode":129,"cosmosGeoPoint":139,"geoPoint":143,"contacts":37},"nstituto Clinico Humanitas","Rozzano","20089",{"type":73,"coordinates":140},[141,142],9.1559,45.38193,{"lat":142,"lon":141},{"facility":145,"status":80,"city":146,"state":37,"zip":37,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":37},"Antoni van Leeuwenhoek","Amsterdam","Netherlands","NL",{"type":73,"coordinates":150},[151,152],4.88969,52.37403,{"lat":152,"lon":151},{"facility":155,"status":80,"city":156,"state":37,"zip":37,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":37},"Hospital HM Nou Delfos","Barcelona","Spain","ES",{"type":73,"coordinates":160},[161,162],2.15899,41.38879,{"lat":162,"lon":161},{"facility":165,"status":80,"city":156,"state":37,"zip":37,"country":157,"countryCode":158,"cosmosGeoPoint":166,"geoPoint":168,"contacts":37},"VHIO, Vall d'Hebron University Hospital",{"type":73,"coordinates":167},[161,162],{"lat":162,"lon":161},{"facility":170,"status":80,"city":171,"state":37,"zip":37,"country":157,"countryCode":158,"cosmosGeoPoint":172,"geoPoint":176,"contacts":37},"Centro Integral Oncologico Clara Campal","Madrid",{"type":73,"coordinates":173},[174,175],-3.70256,40.4165,{"lat":175,"lon":174},{"facility":178,"status":80,"city":171,"state":37,"zip":37,"country":157,"countryCode":158,"cosmosGeoPoint":179,"geoPoint":181,"contacts":37},"Hospital Universitario Fundacion Jimenez Diaz",{"type":73,"coordinates":180},[174,175],{"lat":175,"lon":174},{"type":183,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100580655","phase-1-phase-12-study-of-imc-r117c-in-selected-advanced-cancers-100580655",false,"NCT06840119","Phase 1\u002F2 Study of IMC-R117C in Selected Advanced Cancers","A Phase 1\u002F2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* HLA-A\\*02:01-positive\n* Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma\n* Archived or fresh tumor tissue sample that must be confirmed as adequate\n* Evaluable\u002FMeasurable disease per RECIST 1.1\n* Previously received applicable standard treatments\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* Symptomatic or untreated central nervous system metastasis\n* Recent bowel obstruction\n* Ongoing ascites or effusion requiring recent drainages\n* Significant ongoing toxicity from prior anticancer treatment\n* Out-of-range laboratory values\n* Clinically significant lung, heart, or autoimmune disease\n* Ongoing requirement for immunosuppressive treatment\n* Significant secondary malignancy\n* Hypersensitivity to study drug or excipients\n* Pregnant or lactating","ALL","18 Years",{"count":194,"type":195},600,"ESTIMATED","INTERVENTIONAL",[198,199],"PHASE1","PHASE2","This phase 1\u002F2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.",[202,203],"Cancer","HLA-A*02:01-positive","2026-01-26",{"date":206,"type":207},"2026-01-28","ACTUAL",{"date":209,"type":207},"2024-01-10",{"date":211,"type":195},"2027-11-30",{"name":5,"class":6},13]